Green Square Capital LLC bought a new stake in Stryker Corporation (NYSE:SYK) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,211 shares of the medical technology company’s stock, valued at approximately $424,000.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Stryker Corporation by 5.2% in the first quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock worth $3,083,382,000 after buying an additional 1,161,688 shares in the last quarter. BlackRock Inc. raised its position in shares of Stryker Corporation by 2,526.4% in the first quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock worth $2,893,242,000 after buying an additional 21,140,000 shares in the last quarter. Fundsmith LLP raised its position in shares of Stryker Corporation by 4.6% in the first quarter. Fundsmith LLP now owns 5,175,453 shares of the medical technology company’s stock worth $681,348,000 after buying an additional 226,057 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Stryker Corporation by 0.5% in the first quarter. Wellington Management Group LLP now owns 4,569,118 shares of the medical technology company’s stock worth $601,525,000 after buying an additional 24,139 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Stryker Corporation by 6.3% in the first quarter. Geode Capital Management LLC now owns 2,786,406 shares of the medical technology company’s stock worth $366,255,000 after buying an additional 166,133 shares in the last quarter. 73.99% of the stock is currently owned by institutional investors and hedge funds.

Shares of Stryker Corporation (NYSE SYK) traded down 0.47% during mid-day trading on Thursday, hitting $144.50. 169,030 shares of the stock were exchanged. The stock has a market cap of $54.05 billion, a PE ratio of 32.25 and a beta of 0.80. The company has a 50-day moving average of $143.54 and a 200 day moving average of $135.29. Stryker Corporation has a one year low of $106.48 and a one year high of $148.84.

Stryker Corporation (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.98 billion. During the same quarter in the prior year, the firm earned $1.39 earnings per share. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, equities analysts predict that Stryker Corporation will post $6.50 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be paid a dividend of $0.425 per share. This represents a $1.70 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s payout ratio is 37.95%.

WARNING: “Green Square Capital LLC Buys New Stake in Stryker Corporation (NYSE:SYK)” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/10/green-square-capital-llc-buys-new-stake-in-stryker-corporation-nysesyk.html.

SYK has been the topic of a number of research reports. Cowen and Company set a $150.00 price target on shares of Stryker Corporation and gave the company an “outperform” rating in a research note on Wednesday, April 26th. Morgan Stanley reaffirmed an “overweight” rating and issued a $160.00 price target (up from $155.00) on shares of Stryker Corporation in a research note on Monday, July 10th. Cantor Fitzgerald initiated coverage on shares of Stryker Corporation in a research note on Thursday, June 29th. They issued a “neutral” rating and a $153.00 price target on the stock. Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price target on the stock in a research note on Monday, July 17th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $140.00 price target (up from $135.00) on shares of Stryker Corporation in a research note on Wednesday, April 26th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. Stryker Corporation presently has an average rating of “Hold” and a consensus target price of $144.03.

In related news, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the transaction, the insider now owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Floyd sold 19,305 shares of the company’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The disclosure for this sale can be found here. Insiders have sold 32,810 shares of company stock worth $4,754,958 in the last three months. Insiders own 7.40% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.